Mody-3: Novel HNF1A mutation and the utility of glucagon-like peptide (GLP)-1 receptor agonist therapy

Endocrine Practice

Volumn 20, Issue 2, 2014, Pages 107-111

  Docena, Maricor K ^a   Faiman, Charles ^b   Stanley, Christine M ^c   Pantalone, Kevin M ^b  

^a SUMMA HEALTH SYSTEM   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Courtagen Life Sciences Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HNF1A PROTEIN, HUMAN;

ADULT; AGONISTS; DIABETES MELLITUS, TYPE 2; FEMALE; GENETICS; HUMAN; MUTATION;

ADULT; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HUMANS; MUTATION;

EID: 84894121269     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP13254.OR     Document Type: Article

References (29)

1. Fajans SS. Scope and heterogeneous nature of MODY. Diabetes Care. 1990;13:49-64.
2. Fajans SS, Bell GI. MODY: History, genetics, pathophysiology, and clinical decision making. Diabetes Care. 2011;34:1878-1884.
3. Owen K, Hattersley AT. Maturity-onset diabetes of the young: from clinical description to molecular genetic characterization. Best Pract Res Clin Endocrinol Metab. 2001;15:309-323.
4. Klupa T, Warram JH, Antonellis A, et al. Determinants of the development of diabetes (maturity-onset diabetes of the young-3) in carriers of HNF-1alpha mutations: evidence for parent-of-origin effect. Diabetes Care. 2002;25:2292-2301.
5. Glucksmann MA, Lehto M, Tayber O, et al. Novel mutations and a mutational hotspot in the MODY3 gene. Diabetes. 1997;46:1081-1086.
6. Yamagata K. Regulation of pancreatic beta-cell function by the HNF transcription network: Lessons from maturity-onset diabetes of the young (MODY). Endocr J. 2003;50:491-499.
7. Yamagata K, Oda N, Kaisaki PJ, et al. Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature. 1996;384:455-458.
8. Ellard S, Colclough K. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF1A) and 4 alpha (HNF4A) in maturity-onset diabetes of the young. Hum Mutat. 2006;27:854-869.
9. Awa WL, Thon A, Raile K, et al. Genetic and clinical characteristics of patients with HNF1A gene variations from the german-austrian DPV database. Eur J Endocrinol. 2011;164:513-520.
10. Barrio R, Bellanné-Chantelot C, Moreno JC, et al. Nine novel mutations in maturity-onset diabetes of the young (MODY) candidate genes in 22 Spanish families. J Clin Endocrinol Metab. 2002;87:2532-2539.
11. Bellanné-Chantelot C, Carette C, Riveline JP, et al. The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3. Diabetes. 2008;57:503-508.
12. Harries LW, Ellard S, Stride A, Morgan NG, Hattersley AT. Isomers of the TCF1 gene encoding hepatocyte nuclear factor-1 alpha show differential expression in the pancreas and define the relationship between mutation position and clinical phenotype in monogenic diabetes. Hum Mol Genet. 2006;15:2216-2224.
13. Fajans SS, Bell GI. Phenotypic heterogeneity between different mutations of MODY subtypes and within MODY pedigrees. Diabetologia. 2006;49:1106-1108.
14. Kim SH, Ma X, Klupa T, et al. Genetic modifiers of the age at diagnosis of diabetes (MODY3) in carriers of hepatocyte nuclear factor-1alpha mutations map to chromosomes 5p15, 9q22, and 14q24. Diabetes. 2003;52:2182-2186.
15. Søvik O, Njølstad P, Følling I, Sagen J, Cockburn BN, Bell GI. Hyperexcitability to sulphonylurea in MODY3. Diabetologia. 1998;41:607-608.
16. Pearson ER, Liddell WG, Shepherd M, Corrall RJ, Hattersley AT. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes. Diabet Med. 2000;17:543-545.
17. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248-249.
18. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res. 2001;11:863-874.
19. Chi YI. Homeodomain revisited: A lesson from disease-causing mutations. Hum Genet. 2005;116:433-444.
20. Bjørkhaug L, Bratland A, Njølstad PR, Molven A. Functional dissection of the HNF-1alpha transcription factor: A study on nuclear localization and transcriptional activation. DNA Cell Biol. 2005;24:661-669.
21. Chi YI, Frantz JD, Oh BC, Hansen L, Dhe-Paganon S, Shoelson SE. Diabetes mutations delineate an atypical POU domain in HNF-1alpha. Mol Cell. 2002;10:1129-1137.
22. Chèvre JC, Hani EH, Boutin P, et al. Mutation screening in 18 Caucasian families suggest the existence of other MODY genes. Diabetologia. 1998;41:1017-1023.
23. Sahu RP, Aggarwal A, Zaidi G, et al. Etiology of early-onset type 2 diabetes in Indians: Islet autoimmunity and mutations in hepatocyte nuclear factor 1alpha and mitochondrial gene. J Clin Endocrinol Metab. 2007;92:2462-2467.
24. Yorifuji T, Fujimaru R, Hosokawa Y, et al. Comprehensive molecular analysis of japanese patients with pediatric-onset MODY-type diabetes mellitus. Pediatr Diabetes. 2012;13:26-32.
25. Vilsbøll T, Knop FK, Krarup T, et al. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab. 2003;88:4897-4903.
26. Ahrén B, Sörhede Winzell M, Burkey B, Hughes TE. Beta-cell expression of a dominant-negative HNF-1alpha compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice. Eur J Pharmacol. 2005;521:164-168.
27. Ahluwalia R, Perkins K, Ewins D, Goenka N. Exenatide-a potential role in treatment of HNF1-alpha MODY in obese patients? Diabet Med. 2009;26:834-835.
28. Lumb AN, Gallen IW. Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin (1). Diabet Med. 2009;26:189-190.
29. Katra B, Klupa T, Skupien J, et al. Dipeptidyl peptidase-IV inhibitors are efficient adjunct therapy in HNF1A maturity-onset diabetes of the young patients-report of two cases. Diabetes Technol Ther. 2010;12:313-316.